Table 1

Demographic distribution of screened population and enrolled participants by treatment

Screened population (n = 511)Total enrolled (n = 180)Treatment group
Placebo (n = 90)Chlorophyllin (n = 90)
Gender*
 Male172 (33.7)49 (27.2)30 (33.3)19 (21.1)
 Female339 (66.3)131 (72.8)60 (66.7)71 (78.9)
Age, years44 (35, 51)42 (34, 49)43 (35, 49)41 (33, 49)
Body mass index22.9 (20.8, 25.2)22.4 (20.7, 24.2)22.4 (20.7, 24.7)22.4 (20.8, 23.9)
Hepatitis B surface antigen, positive*42 (8.2)8 (4.4)3 (3.3)5 (5.6)
Aflatoxin–albumin adduct, pmol/mg protein0.41 (0.17, 0.77)0.50 (0.30, 0.87)0.55 (0.32, 0.90)0.47 (0.29, 0.84)
  • * n (%). 

  • Median (interquartile range). 

  • Two hundred and thirty-eight individuals were screened for levels of aflatoxin–albumin adducts.